Delving into the Latest Updates on ArgiNOx Pharmaceuticals, Inc. with Synapse

A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH Study

开始日期2005-08-24

申办/合作机构

ArgiNOx Pharmaceuticals, Inc.

EUCTR2005-000412-27-DE / Not yet recruitingN/A

A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH Study

开始日期2005-08-05

申办/合作机构

ArgiNOx Pharmaceuticals, Inc.

EUCTR2005-000412-27-HU / Not yet recruitingN/A

A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH Study

开始日期2005-08-01

申办/合作机构

ArgiNOx Pharmaceuticals, Inc.

100 项与 ArgiNOx Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 ArgiNOx Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 ArgiNOx Pharmaceuticals, Inc. 相关的文献（医药）

2008-09-02·Circulation

Response to Letter Regarding Article, “Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarct”

作者: DelFraino, Brian ; Wang, Zeneng ; Nicholls, Stephen J. ; Panza, Julio A. ; Nissen, Steven E. ; Levison, Bruce ; Hathaway, David ; Griffith, Owen W. ; Koeth, Robert ; Dzavik, Vladimir ; Hochman, Judith S. ; Hazen, Stanley L.

We thank Drs Stuehlinger, Metzler, and Cooke for their interest and comments on our study. We agree that the mechanism(s) promoting increased systemic levels of asymmetric dimethylarginine (ADMA) in the setting of acute myocardial infarction complicated by cardiogenic shock may be multifactorial and remains to be fully elucidated. We agree that ADMA may be elevated as a consequence of myocardial ischemia or reperfusion and that ADMA may play a role in the pathogenesis of …

2007-11-13·Circulation1区 · 医学

Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction

1区 · 医学

Article

作者: Panza, Julio A. ; Griffith, Owen W. ; Hochman, Judith S. ; Nicholls, Stephen J. ; Dzavik, Vladimir ; Hathaway, David ; DelFraino, Brian ; Koeth, Robert ; Wang, Zeneng ; Levison, Bruce ; Nissen, Steven E. ; Hazen, Stanley L.

Background— It is unclear whether abnormalities of arginine and nitric oxide metabolism are related to hemodynamic dysfunction and mortality in patients with cardiogenic shock (CS) after acute myocardial infarction. Methods and Results— Plasma metabolites reflecting arginine bioavailability, nitric oxide metabolism, and protein oxidation were analyzed by mass spectrometry in patients with CS (n=79) and age- and gender-matched patients with coronary artery disease and normal left ventricular function (n=79). CS patients had higher levels of asymmetric dimethylarginine (ADMA; P <0.0001), symmetric dimethylarginine ( P <0.0001), monomethylarginine ( P =0.0003), nitrotyrosine ( P <0.0001), and bromotyrosine ( P <0.0001) and lower levels of arginine ( P <0.0001), ratio of arginine to ornithine ( P =0.03), and ratio of arginine to ornithine plus citrulline) ( P =0.0003). CS patients with elevated ADMA levels were 3.5-fold (95% confidence interval, 1.4 to 11.3; P =0.02) more likely to die in 30 days than patients with low ADMA levels. ADMA remained the only independent predictor of mortality on multiple logistic regression analysis. In patients with normal renal function, symmetric dimethylarginine levels inversely correlated with mean arterial pressure and systemic vascular resistance, whereas levels of ADMA correlated with pulmonary capillary wedge pressure and both systolic and diastolic pulmonary artery pressures. Despite dramatic elevations, levels of protein oxidation products did not predict hemodynamic dysfunction or mortality in CS patients. Conclusions— CS is characterized by an arginine-deficient and highly specific pro-oxidant state, with elevated levels of methylated arginine derivatives, including endogenous nitric oxide synthase inhibitors. Levels of methylated arginine derivatives strongly correlate with hemodynamic dysfunction. Among all clinical and laboratory parameters monitored, ADMA levels were the strongest independent predictor of 30-day mortality.

100 项与 ArgiNOx Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 ArgiNOx Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息